常茂生物(00954.HK)2019年淨利增15.39%至5829.9萬元 末期息0.055元
格隆匯3月27日丨常茂生物(00954.HK)公佈,截至2019年12月31日止年度,公司實現收入4.95億元人民幣(單位下同),同比減22.62%;期內歸屬於公司權益持有人的利潤5829.9萬元,同比增長15.39%;基本每股盈利0.11元;擬派末期現金股息每股0.055元(含税)。
收入減少主要是由於銷售量較2018年減少所致。受2019年第四季度環保設施提升改造的影響,集團常州工廠於十月至十一月期間暫停生產,對部分暢銷產品的供應形成一定製約,降低了銷量,從而影響了第四季度乃至全年的銷售收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.